| Esophageal cancer | Gastric cancer | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
probability | probability | |||||||||||||
low | middle | high | p value | low | middle | high | p value | |||||||
N | % | N | % | N | % | Â | Â | Â | Â | Â | Â | Â | Â | |
ALL | 477 | 100% | 548 | 100% | 625 | 100% | Â | 507 | 100% | 327 | 100% | 545 | 100% | Â |
Sex | Â | Â | Â | Â | Â | Â | 0.75 | Â | Â | Â | Â | Â | Â | 0.53 |
Female | 136 | 29% | 147 | 27% | 179 | 29% | Â | 199 | 39% | 122 | 37% | 224 | 41% | Â |
Male | 341 | 71% | 401 | 73% | 446 | 71% | Â | 308 | 61% | 205 | 63% | 321 | 59% | Â |
Age | Â | Â | Â | Â | Â | Â | 0.09 | Â | Â | Â | Â | Â | Â | 0.72 |
 < 60 | 100 | 21% | 83 | 15% | 111 | 18% |  | 76 | 15% | 46 | 14% | 71 | 13% |  |
60—74 | 239 | 50% | 287 | 52% | 340 | 54% |  | 169 | 33% | 122 | 37% | 195 | 36% |  |
 ≥ 75 | 138 | 29% | 178 | 32% | 174 | 28% |  | 262 | 52% | 159 | 49% | 279 | 51% |  |
cT Classification | Â | Â | Â | Â | Â | Â | 0.59 | Â | Â | Â | Â | Â | Â | 0.03 |
cT1 | 28 | 6% | 35 | 6% | 34 | 5% | Â | 21 | 4% | 12 | 4% | 29 | 5% | Â |
cT2 | 133 | 28% | 143 | 26% | 197 | 32% | Â | 202 | 40% | 117 | 36% | 190 | 35% | Â |
cT3 | 239 | 50% | 273 | 50% | 305 | 49% | Â | 130 | 26% | 66 | 20% | 117 | 21% | Â |
cT4 | 6 | 1% | 10 | 2% | 10 | 2% | Â | 16 | 3% | 20 | 6% | 19 | 3% | Â |
cTX | 71 | 15% | 87 | 16% | 79 | 13% | Â | 138 | 27% | 112 | 34% | 190 | 35% | Â |
cN Classification | Â | Â | Â | Â | Â | Â | 0.22 | Â | Â | Â | Â | Â | Â | 0.7 |
cN0 | 176 | 37% | 211 | 39% | 272 | 44% | Â | 275 | 54% | 182 | 56% | 317 | 58% | Â |
cN +  | 260 | 55% | 288 | 53% | 303 | 48% |  | 161 | 32% | 99 | 30% | 151 | 28% |  |
cNX | 41 | 9% | 49 | 9% | 50 | 8% | Â | 71 | 14% | 46 | 14% | 77 | 14% | Â |
Histology | Â | Â | Â | Â | Â | Â | 0.07 | Â | Â | Â | Â | Â | Â | 0.475 |
Adenocarcinoma | 348 | 73% | 386 | 70% | 477 | 76% | Â | 491 | 97% | 321 | 98% | 532 | 98% | Â |
Squamous cell carcinoma | 123 | 26% | 145 | 26% | 134 | 21% | Â | NA | Â | NA | Â | NA | Â | Â |
Not otherwise specified | 6 | 1% | 17 | 3% | 14 | 2% | Â | 16 | 3% | 6 | 2% | 13 | 2% | Â |
Number of Comorbidities | Â | Â | Â | Â | Â | Â | 0.83 | Â | Â | Â | Â | Â | Â | 0.01 |
0 comorbidities | 192 | 40% | 213 | 39% | 259 | 41% | Â | 166 | 33% | 127 | 39% | 219 | 40% | Â |
1 comorbidity | 151 | 32% | 184 | 34% | 204 | 33% | Â | 187 | 37% | 111 | 34% | 153 | 28% | Â |
2 or more | 116 | 24% | 117 | 21% | 141 | 23% | Â | 135 | 27% | 74 | 23% | 150 | 28% | Â |
unknown | 18 | 4% | 34 | 6% | 21 | 3% | Â | 19 | 4% | 15 | 5% | 23 | 4% | Â |
ECOG performance status | Â | Â | Â | Â | Â | Â | 0.53 | Â | Â | Â | Â | Â | Â | 0.001 |
ECOG 0 and 1 | 319 | 67% | 368 | 67% | 415 | 66% | Â | 260 | 51% | 141 | 43% | 267 | 49% | Â |
ECOG 2 | 39 | 8% | 53 | 10% | 43 | 7% | Â | 37 | 7% | 24 | 7% | 51 | 9% | Â |
ECOG 3 and 4 | 16 | 3% | 16 | 3% | 17 | 3% | Â | 31 | 6% | 10 | 3% | 12 | 2% | Â |
Unknown ECOG | 103 | 22% | 111 | 20% | 150 | 24% | Â | 179 | 35% | 152 | 46% | 215 | 39% | Â |